Long-term prophylaxis with lanadelumab for HAE: authorization for temporary use in France.
Olivier FainAurelie Du-ThanhDelphine GobertDavid LaunayNeil InhaberKarima BoudjemiaMagali AubineauAlain SobelIsabelle Boccon-GibodLaurence WeissLaurence BouilletPublished in: Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology (2022)
Lanadelumab reduced attack rates, improved quality of life, and was generally well tolerated.
Keyphrases